About 70% of breast cancers express estrogen hormone receptor (ER) and/or progesterone receptor (PR), and these markers along with human epidermal growth factor receptor 2 (HER-2) and proliferation marker Ki-67 provide information about tumor grade and possible response to different treatments [6]. This evidence concerns the gene ERBB2 and breast carcinoma.